
ENHANZE® Partnered Products

Halozyme's rHuPH20 is approved across multiple indications by regulatory agencies around the world to facilitate subcutaneous (SC) administration of co-administered drugs.

Solutions and Potential Benefits | Partnered Products | Framework For Success

ENHANZE® Partnered Products



Janssen

DARZALEX FASPRO® (daratumumab and hyaluronidase human-fihj) (U.S./China)

DARZALEX® SC (daratumumab) (Outside U.S.)

DARZQURO® (daratumumab) (Japan)

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) (U.S.)

RYBREVANT® SC (amivantamab) (EU)

RYBROFAZ® (amivantamab) (Japan)

Takeda

HYQVIA® [immune globulin infusion 10% (Human) with recombinant human

Petitioner Merck, Ex. 1212, p. 1
Merck Sharp & Dohme LLC v. Halozyme Inc.
IPR2026-00314

hyaluronidase]

argenx

VYVGART® HYTRULO (efgartigimod alfa and hyaluronidase-qvfc) (U.S.)

VYVGART® (efgartigimod alfa) solution for injection (EU)

VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) combination subcutaneous injection (Japan)

Roche

PHESGO® (pertuzumab/trastuzumab/hyaluronidase-zzxf) (U.S.) (pertuzumab/trastuzumab) (EU)

TECENTRIQ HYBREZA™ (atezolizumab and hyaluronidase-tqjs) (U.S.)

TECENTRIQ® SC (atezolizumab) (Outside U.S.)

OCREVUS ZUNOVO™ (ocrelizumab and hyaluronidase-ocsq) (U.S.)

OCREVUS® SC (ocrelizumab) (EU)

RITUXAN HYCELA® (rituximab/hyaluronidase human) (U.S.)

MabThera® SC (rituximab) (Outside U.S.)

HERCEPTIN HYLECTA™ SC (trastuzumab and hyaluronidase-oysk) (U.S.)

Herceptin® SC (trastuzumab) (Outside U.S.)

Bristol Myers Squibb

Opdivo Qvantig™ (nivolumab and hyaluronidase-nvhy) (U.S.)

Petitioner Merck, Ex. 1212, p. 2
Merck Sharp & Dohme LLC v. Halozyme Inc.
IPR2026-00314

ENHANZE® by the Numbers



Commercial

10 commercial partnered products with ENHANZE® licensing

1 million patients treated in **100+** global markets

10s of billions of dollars in cumulative partner product sales

Regulatory

20+ partner programs to FIH dosing

100% success record (10 for 10) of regulatory approvals

Technical

100% of 40+ monoclonal antibodies tested to date demonstrated short term compatibility

2,500+ subjects characterized for immunogenicity across **18+** studies

2 commercial-scale GMP sources for robust rHuPH20 supply

Halozyme

Cookie Settings
Privacy Policy
Careers
Contact

Petitioner Merck, Ex. 1212, p. 3
Merck Sharp & Dohme LLC v. Halozyme Inc.
IPR2026-00314

© 2015-2024, Halozyme, Inc.
All rights reserved.
All trademarks belong to their respective owners.

Petitioner Merck, Ex. 1212, p. 4
Merck Sharp & Dohme LLC v. Halozyme Inc.
IPR2026-00314